Advanced Tumors
22
6
7
9
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.6%
3 terminated out of 22 trials
75.0%
-11.6% vs benchmark
0%
0 trials in Phase 3/4
33%
3 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 9 completed trials
Clinical Trials (22)
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor
Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.
A Study of AL58805 in Patients With Advanced Tumors
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)
A SHR-1210 BE Study on Healthy Subjects
Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
A Study of HRS2543 in Patients With Advanced Tumors
A Study of CS23546 in Subjects With Advanced Tumors
Phase I Study of CPI-300 in Patients With Advanced Tumors
A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma
A Study of PM1022 in Patients With Advanced Tumors
Study of CPI-100 in Patients With Advanced Tumors